

GREGG HUBER ALTON

Work:

333 Lakeside Drive
Foster City, CA 94404
(650) 522-5783 (0)

Home:

(b)(6)
(b)(6) (M)

EXPERIENCE

GILEAD SCIENCES, INC.

8/09 – Present **Executive Vice President, Corporate and Medical Affairs**
7/05 – 8/09 **Senior Vice President, General Counsel and Secretary**
7/01 – 7/05 **Vice President, General Counsel and Assistant Secretary**
3/00 – 7/01 **General Counsel (Senior Director)**
10/99 – 3/00 **Associate General Counsel (Director)**

Reports directly to the Chief Executive Officer, responsible for commercial and access operations in Asia, Latin America and Africa, Government Affairs and Policy, Public Affairs, and Medical Affairs of publicly traded, Fortune 500 biopharmaceutical company. Gilead is the market leader in HIV/AIDS, viral hepatitis and in the emerging area of cellular therapy, which offers a new approach to treating cancer. The company also has a broad pipeline of investigational compounds, with more than 150 Phase 2 and 3 clinical studies evaluating compounds with the potential to become the next generation of innovative therapies for HIV, liver diseases, cancer, and serious respiratory and inflammatory conditions.

Serves as Member of Chief Executive Officer's Leadership Team and Executive Committee.

Acts as Chair and Member of Board of Gilead Healthcare PAC, as well as Member of Board of Gilead Foundation.

Leads the following business areas for Gilead:

- **Access Operations and Emerging Markets.** Manages programs in developing and emerging markets, enabling access to Gilead's products in Latin America, the Caribbean, Central and Southeast Asia, and Africa, through direct sales and distribution partnerships, including staff of 100. Through program, number of people in resource-limited countries receiving Gilead HIV medicines each day has grown from 100 in 2003 to more than 10 million in 2018. Additionally, more than 910,000 people with chronic hepatitis C virus have been treated through this program. Company has used generic licensing partnerships to establish low-cost manufacturing capability for these markets, tiered pricing based on ability to pay and disease prevalence, and partnerships with NGOs, foundations and donors, to expedite patient access. Programs have helped reduce the lowest price of generic Gilead HIV therapy by 87 percent since 2006, and today include efforts to expand access to HIV pre-exposure prophylaxis (PrEP).

- **Asia Commercial Operations.** Manages commercial operations for Gilead’s Asia affiliates, including staff of 60. Department is responsible for distribution of Gilead’s products in commercial markets in the region, including recent launch of product for chronic hepatitis C virus in China.
- **Government Affairs and Policy.** Manages global Government Affairs department and associated policy activities with a staff of approximately 80. Partners with governments, public officials, healthcare providers, healthcare organizations and industry to help develop long-term policies, strategies and solutions that encourage innovation and break down barriers to care and treatment. Activities include global access initiatives, intellectual property rights policy, reimbursement, disease awareness and screening, testing and linkage to care, pandemic planning and treatment guidelines. Notable achievements include FOCUS, a public-private partnership to implement routine HIV and viral hepatitis screening in U.S. healthcare settings.
- **Public Affairs.** Manages global Public Affairs department with staff of approximately 60. Department is responsible for communicating and advocating Gilead's vision, mission and values, as well as key milestones related to corporate, product, and research and development to key external audiences through a variety of media and through direct contact. Department manages numerous advertising, branding and public relations agencies. Activities include building and maintaining relationships with patient advocacy groups and NGOs, and supporting product launches, disease awareness campaigns and health policy campaigns. Recent initiatives include COMPASS, a \$100-million, 10-year program to address the HIV/AIDS epidemic in the Southern United States.
- **Medical Affairs.** Manages global Medical Affairs department with a staff of approximately 550. Department is responsible for Phase IV clinical trial strategies, investigator-sponsored research, medical education, HIV prevention research, awareness and education, interface with key opinion leaders, and medical information and publication planning across all of Gilead's therapeutic areas of focus. Notable achievements include collaboration with U.S. and international partners to implement landmark studies demonstrating the effectiveness of HIV PrEP, with diverse trial participants representing heavily affected populations and geographic regions.

COOLEY GODWARD LLP, Palo Alto, CA

7/98 –10/99

Corporate Associate – Mergers and Acquisitions Group

11/93 -12/96

Mergers and Acquisitions: Advised and represented high technology and biotechnology clients in all phases of transactions. Determined appropriate transaction structures, and negotiated and drafted all documentation including term sheets, confidentiality agreements, standstill agreements, no-shop agreements and definitive and ancillary documentation. Managed due diligence process and prepared disclosure documents.

General Corporate: Counseled clients in initial and follow-on public offerings (issuer-side and underwriter-side, equity and debt), private placements, press releases and 1934 Act reports, corporate governance, corporate structure, business strategy, takeover defenses and other corporate matters. Acted as primary contact for, and oversaw representation of, clients in matters such as employee benefits, employment disputes, real estate, litigation and intellectual property protection.

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPECO, P.C., Boston, MA

1/97 – 1/98

Corporate Associate

Represented primarily high technology and biotechnology clients in transactions including mergers and acquisitions, initial and follow-on public offerings (issuer-side and underwriter- side), private placements, including a private placement of public equity (PIPE), collaborations and licensing transactions.

OTHER ACTIVITIES

THE AIDS INSTITUTE

Member of the Board of Directors

BOYS & GIRLS CLUB OF OAKLAND

Member of the Board of Directors

UNIVERSITY OF CALIFORNIA AT BERKELEY COLLEGE OF LETTERS & SCIENCE

Member of the Advisory Board

DEPARTMENT OF COMMERCE

Member of the Industry Trade Advisory Committee on Intellectual Property Rights

PARTNERS IN HEALTH

Member of the Board of Trustees

PHARMOZYME INC.

Member of the Advisory Board

USC SCHAEFFER CENTER FOR HEALTH POLICY AND ECONOMICS

Member of the Advisory Board

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO GLOBAL HEALTH GROUP

Member of the Advisory Board

STANFORD LAW SCHOOL

Member of the Dean's Advisory Council

AIDS HEALTHCARE FOUNDATION

Previous Member of the Board of Directors, Chair of Finance Committee, Treasurer

BAYBIO (BAY AREA BIOSCIENCE ASSOCIATION)

Previous Member of the Board of Directors, Chairman (2006)

CELLADON CORPORATION

Previous Member of the Board of Directors

COLLIDION CORPORATION

Previous Member of the Board of Directors

OCULUS INNOVATIVE SCIENCES, INC.

Previous Member of the Board of Directors, Audit Committee

PHYTOGEN LIFE SCIENCES

Previous Member of the Board of Directors, Audit Committee

EDUCATION

STANFORD LAW SCHOOL, Stanford, CA

Juris Doctorate, 1993

Native American Law Students Association (President 1992)

Environmental Law Journal, Environmental Law Society

UNIVERSITY OF CALIFORNIA AT BERKELEY, Berkeley, CA

Bachelor of Arts, Legal Studies, 1989